IonMed
Cold Plasma Bio-welding Technology for Wound Closure
Health Tech & Life Sciences
Non Active, Jul 2019 ceased to operate
Company Overview
Snapshot
Founded in November 2009 by Ronen Lam and Amnon Lam, IonMed operated with 1–10 employees. The company ceased operations in July 2019.
Business overview
IonMed is a Health Tech & Life Sciences company focused on developing plasma-based technology for advanced clinical applications. Its core product, BioWeld1, is a cold plasma device designed for wound and surgical incision closure and skin-graft fixation, utilizing dedicated disposable tips and a biological film. The company targets the medical devices and medical treatment & therapeutics markets, serving healthcare providers and hospitals with its B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- What is IonMed's core technology?
- IonMed develops a plasma-based technology, specifically its BioWeld1 cold plasma system, for medical applications such as wound closure and skin-graft fixation.
- When did IonMed cease operations?
- IonMed ceased to operate in July 2019.
- What was a significant regulatory milestone for IonMed's BioWeld1 system?
- In October 2014, IonMed received CE Mark clearance for its BioWeld1 cold plasma system for surgical incision closure, enabling commercialization in the EU.
- What clinical trial results did IonMed announce in 2015?
- In November 2015, IonMed completed clinical trials for its BioWeld1 cold-plasma system, demonstrating its advantages in skin-graft fixation over traditional methods like sutures, fibrin glue, or staples, with no reported infections.
- Which investors participated in IonMed's December 2009 funding round?
- In December 2009, IonMed received funding from The Trendlines Group and General Oriental Investments.